Filgotinib, which has been approved for use in rheumatoid arthritis (RA) [7] and ulcerative colitis [8], is a JAK1 preferential inhibitor that suppresses downstream signals of IL-6, and it was anticipated that filgotinib would also be effective in iMCD. The gene discussed is JAK1; the disease is rheumatoid arthritis.